Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M206126200 on July 18, 2002

J. Biol. Chem., Vol. 277, Issue 38, 35393-35401, September 20, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/38/35393    most recent
M206126200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yarov-Yarovoy, V.
Right arrow Articles by Catterall, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yarov-Yarovoy, V.
Right arrow Articles by Catterall, W. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Role of Amino Acid Residues in Transmembrane Segments IS6 and IIS6 of the Na+ Channel alpha  Subunit in Voltage-dependent Gating and Drug Block*

Vladimir Yarov-Yarovoy, Jancy C. McPhee, Diane Idsvoog, Caroline Pate, Todd Scheuer, and William A. CatterallDagger

From the Department of Pharmacology, University of Washington, Seattle, Washington 98195-7280

Received for publication, June 20, 2002, and in revised form, July 16, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Alanine-scanning mutagenesis of transmembrane segments IS6 and IIS6 of the rat brain Nav1.2 channel alpha  subunit identified mutations N418A in IS6 and L975A in IIS6 as causing strong positive shifts in the voltage dependence of activation. In contrast, mutations V424A in IS6 and L983A in IIS6 caused strong negative shifts. Most IS6 mutations opposed inactivation from closed states, but most IIS6 mutations favored such inactivation. Mutations L421C and L983A near the intracellular ends of IS6 and IIS6, respectively, exhibited significant sustained Na+ currents at the end of 30-ms depolarizations, indicating a role for these residues in Na+ channel fast inactivation. These residues, in combination with residues at the intracellular end of IVS6, are well situated to form an inactivation gate receptor. Mutation I409A in IS6 reduced the affinity of the local anesthetic etidocaine for the inactivated state by 6-fold, and mutations I409A and N418A reduced use-dependent block by etidocaine. No IS6 or IIS6 mutations studied affected inactivated-state affinity or use-dependent block by the neuroprotective drug sipatrigine (compound 619C89). These results suggest that the local anesthetic receptor site is formed primarily by residues in segments IIIS6 and IVS6 with the contribution of a single amino acid in segment IS6.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Voltage-gated Na+ channels are integral membrane proteins that are responsible for the initiation and propagation of action potentials in nerve and muscle cells (1-5). The rat brain Na+ channel as isolated biochemically consists of alpha  (260 kDa), beta 1 (36 kDa), and beta 2 (33 kDa) subunits (2). The alpha  subunit is composed of four homologous domains (I-IV), each with six transmembrane segments (S1-S6) and an additional membrane-reentrant pore loop (P-loop) between segments S5 and S6 (2, 4, 5). Analogous to the structural topology of pore-forming M2 segments of the K+ channel from Streptomyces lividans (KcsA) (6), the S6 segments from each domain of the Na+ channel are thought to be arranged in a square array surrounding the inner pore, whereas P-loops from each domain line the outer pore and form the ion selectivity filter (2, 4, 5).

Voltage-gated Na+ channel activation is thought to result from a voltage-driven outward movement of gating charges, which initiates a conformational change in the protein that opens the channel (7, 8). Analysis of the primary structure of the Na+ channel alpha  subunit led to the prediction that S4 transmembrane segments, which contain repeated motifs of positively charged arginine and lysine residues every three amino acids, might serve as the voltage sensor (9, 10). Depolarization of the membrane was proposed to cause the S4 segments to move outward, inducing a conformational change in the pore of the channel resulting in activation. Site-directed mutagenesis studies have demonstrated that the positively charged residues in all four S4 segments contribute to the voltage-dependent activation of the Na+ channel (11, 12). The proposed outward movement of the S4 segments has been directly detected using mutagenesis, covalent modification, and fluorescent imaging experiments (13-15). Thus, the S4 segments play a critical role in voltage-dependent activation. Na+ channel fast inactivation occurs within a few milliseconds of channel opening and is mediated by the intracellular loop connecting domains III and IV (16, 17). Mutagenesis studies of this loop revealed three hydrophobic residues (isoleucine, phenylalanine, and methionine (IFM motif)) that are critical for fast inactivation (18). Scanning mutagenesis experiments have identified multiple amino acid residues that may form the inactivation gate receptor within and near the intracellular mouth of the pore, including a cluster of three hydrophobic residues at the intracellular end of segment S6 in domain IV (segment IVS6) (19, 20) and residues in intracellular loops S4-S5 in domain III (21) and S4-S5 in domain IV (22-25). The voltage dependence of Na+ channel inactivation derives largely from coupling to the activation process (8). Mutagenesis studies have provided strong evidence that outward movement of the S4 segments in domains III and IV initiates a conformational change that leads to fast inactivation of the Na+ channel by closure of the intracellular inactivation gate (14, 26-28).

Alanine-scanning mutagenesis was previously used to investigate the role of amino acid residues in the S6 transmembrane segments of domains III and IV of the Na+ channel in voltage-dependent gating and block by clinically important drugs (19, 20, 29-31). A number of mutations in segments IIIS6 and IVS6 of the rat brain type IIA Na+ channel alpha  subunit, designated the Nav1.2 channel according to the nomenclature of Goldin et al. (32), produced strong shifts in the voltage dependence of steady-state activation and inactivation, suggesting that the native residues at those positions might play a particularly important role in the voltage-dependent gating of Na+ channels (20, 30). An alpha -helical pattern of the shifts in the voltage dependence of activation and inactivation produced by alanine mutations in the inner two-thirds of segment IIIS6 suggested rotational movement of segment IIIS6 during channel gating (30). Specific amino acid residues in segments IIIS6 and IVS6 were identified that form the receptor sites for Na+ channel pore-blocking drugs such as local anesthetics and antiarrhythmic and anticonvulsant drugs (29-31). Mutations F1764A and Y1771A in segment IVS6 of the rat brain Nav1.2 channel reduced the affinity of inactivated Na+ channels for the local anesthetic etidocaine by 130- and 35-fold, respectively (29). Mutation of Phe1764 and Tyr1771 in the Nav1.2 channel and their homologs in other Na+ channels also substantially reduced block of inactivated Na+ channels by other local anesthetics and antiarrhythmic and anticonvulsant drugs (29, 33-39). Less dramatic disruptions in inactivated-state block by etidocaine were observed with mutations L1465A, N1466A, and I1469A in segment IIIS6 of the rat brain Nav1.2 channel, resulting in 6-, 8-, and 7-fold reduction in affinity, respectively (30). Mutations L1465A and I1469A also reduced the inactivated-state affinity for the anticonvulsant lamotrigine and its congeners (30). Lysine mutations of rat skeletal muscle Nav1.4 channel Ser1276 and Leu1280 (homologous to Leu1465 in the rat brain Nav1.2 channel) in segment IIIS6 reduced the inactivated-state affinity for the local anesthetic bupivacaine by 7-17-fold (40). Lysine mutations of rat skeletal muscle Nav1.4 channel Asn434 and Leu437 in segment IS6 reduced the inactivated-state affinity for etidocaine by 7- and 3-fold, respectively (41).

In this work, we have undertaken a systematic analysis of the role of segments IS6 and IIS6 of the rat brain Nav1.2 channel in channel gating and in block by local anesthetics and anticonvulsant drugs using alanine-scanning site-directed mutagenesis. Our results identify individual residues in segments IS6 and IIS6 that are important for Na+ channel activation and inactivation gating and also define novel determinants of the receptor site for the local anesthetics.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mutagenesis of Rat Brain Nav1.2 Channels-- Mutations were prepared by a two-step PCR protocol using two mutagenic primers and two restriction site primers. The mutagenic fragment and the plasmid pCDM8-Nav1.2 were digested with BstEII and BlpI restriction endonucleases. The mutagenic fragment was then subcloned into the pCDM8-Nav1.2 plasmid via those restriction sites. The mutations were confirmed by restriction mapping and DNA sequence analysis.

Na+ Channel Expression in Xenopus Oocytes-- Plasmids encoding wild-type and mutant Na+ channel alpha  subunits and wild-type beta 1 subunits were linearized, and RNA was transcribed as described previously (20). Xenopus laevis oocytes were harvested, maintained, and injected with RNA by standard methods as described previously (20) with the following modifications. Oocytes were separated and defolliculated by shaking gently for 2 h in 1.5 mg/ml collagenase in 82 mM NaCl, 20 mM MgCl2, 2 mM KCl, and 5 mM HEPES (pH 7.5). After an overnight incubation at 18 °C in 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES (pH 7.4) supplemented with 5% horse serum and 50 mg/ml gentamycin, healthy stage V and VI oocytes were pressure-injected with 55 nl of a 10:1 mixture of wild-type beta 1 and wild-type or mutant rat brain Nav1.2 channel alpha  subunit mRNA, with the alpha  subunit concentration ranging from 10 to 100 ng/µl of injected solution.

Two-microelectrode Voltage-clamp Recordings from Oocytes-- Na+ channel recordings were obtained from injected oocytes using a Dagan CA-1 voltage clamp as described (20). The bath was continuously perfused with Ringer's solution containing 115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, and 10 mM HEPES (pH 7.2), adjusted with NaOH. Recording electrodes contained 3 M KCl and had resistances of <0.5 megaohms. The stock solution of etidocaine (Astra) was dissolved in dimethyl sulfoxide, and sipatrigine (compound 619C89; a generous gift of Dr. Jeff Clare, GlaxoSmithKline) was prepared in 25 mM HCl. Drug stocks were then diluted to the desired concentration in Ringer's solution.

Multiple Sequence Alignment of the S6 Transmembrane Segments of the Rat Brain Nav1.2 Channel-- Multiple sequence alignment of all four S6 transmembrane segments of the rat brain Nav1.2 channel was performed using ClustalX (42). The BOXSHADE program (Version 3.21, written by K. Hofmann and M. Baron) was used for shading the multiple sequence alignment with the fraction of sequences that must agree for shading set to 0.8. This threshold is the fraction of residues that must be identical (black) or similar (gray) for shading to occur.

Three-dimensional Modeling of the S6 Transmembrane Segments of the Rat Brain Nav1.2 Channel-- The KcsA channel structure (6) was used for homology modeling of the S6 transmembrane segments of the rat brain Nav1.2 channel using Molecular Operating Environment software (Chemical Computing Group). The proposed pore-facing residues of the S6 segments of the Nav1.2 channel (see "Results") were aligned with the pore-facing residues of segment M2 of KcsA. The S6 segments were arranged in a clockwise pattern (43, 44).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Effect of Mutations in Segments IS6 and IIS6 on Voltage-dependent Activation of Na+ Channels-- To investigate the functional role of amino acid residues in transmembrane segments IS6 and IIS6 of the rat brain Nav1.2 channel in activation, inactivation, and binding of pore-blocking drugs, we substituted alanine sequentially for the native amino acids at each position from Phe405 to Val424 in segment IS6 and from Phe963 to Leu983 in segment IIS6. Alanine substitution changes the size and chemical properties of the residues, but has little or no effect on protein secondary structure (45, 46). We coexpressed the wild-type (WT)1 or mutant Nav1.2 channel alpha  subunit and the wild-type beta 1 subunit in Xenopus oocytes and used two-microelectrode voltage-clamp recording to measure Na+ currents (Fig. 1, inset). Twenty-nine mutant Nav1.2 channels conducted sufficient Na+ currents for analysis, and 27 of these had rapid kinetics of activation and rapid and complete inactivation like the WT channel (Fig. 1, inset; see Fig. 3 below for analysis of two mutants with altered kinetics of inactivation). Seven alanine mutants in segment IS6 (V408A, S413A, F414A, I417A, I420A, L421A, and V423A) and five alanine mutants in segment IIS6 (V968A, L977A, L979A, L981A, and L982A) did not express sufficient Na+ currents for analysis (generally <0.1 µA). Of the seven residues in segment IS6 that did not express when substituted with alanine, only L421C expressed sufficient Na+ current for analysis when mutated to cysteine.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of point mutations in segments IS6 and IIS6 on Na+ channel activation. Conductance-voltage curves for wild-type (), N418A (open circle ), V424A (black-down-triangle ), L975A (down-triangle), and L983A (black-square) channels are shown. Peak current versus voltage relationships were measured using 30-ms test pulses to potentials from -50 to +70 mV from a holding potential of -90 mV. Conductance was determined as IP/(VR - V), where IP is a peak inward current, VR is the reversal potential, and V is the test pulse voltage. Normalized conductance was fit with a single Boltzmann relationship of the form G(V) = 1/(1 + exp((V - V0.5)/k)), where V0.5 is the half-maximal activation voltage and k is a slope factor. Mean V0.5 and k values were determined for each mutant. The curves shown are plots of the Boltzmann relationship calculated using these mean values. Inset, current traces obtained during depolarizations from the holding potential to 0 mV in oocytes expressing wild-type and V424A channels.

Only four mutations in segments IS6 and IIS6 caused strong positive or negative shifts in the voltage dependence of activation compared with the wild-type channel. Mutations N418A and L975A shifted the voltage for half-maximal activation positively by +21 and +17 mV, respectively (Fig. 1). Mutations V424A and L983A shifted the voltage for half-maximal activation negatively by -11 and -10 mV, respectively (Fig. 1). The slope factor of the voltage dependence of the activation was significantly less steep for N418A (k = 8.0 ± 0.2 mV) and L421C (k = 7.6 ± 0.4 mV) compared with the wild-type channel (k = 5.8 ± 0.2 mV).

Effects of Mutations in Segments IS6 and IIS6 on Steady-state Inactivation of Na+ Channels-- Mutations throughout segments IS6 and IIS6 caused significant shifts in the voltage dependence of inactivation, which was determined using a test pulse applied after a 100-ms voltage step to the indicated membrane potentials. For example, mutations L416A, L421C, and L983A shifted the voltage for half-maximal inactivation positively by +8, +5, and +3 mV, respectively (Fig. 2). The steady-state inactivation curve for L421C and L983A approached nonzero asymptotes with strong depolarizations (Fig. 2). This residual, non-inactivating component of the Na+ current was 6% for L421C and 7% for L983A. Significant positive shifts were also caused by mutations F405A, L411A, Y415A, N418A, and V966A (see Fig. 8, Inactivation Shift). Mutations V424A, M967A, and V974A shifted the voltage for half-maximal inactivation negatively by -7, -11, and -11 mV, respectively (Fig. 2). Significant negative shifts were also caused by mutations I969A, L972A, and N976A (see Fig. 8, Inactivation Shift). Most of the mutations giving significant positive shifts are in segment IS6 (see Fig. 8, red), indicating that native residues at those positions favor closed-state inactivation. In contrast, most of the mutations giving significant negative shifts are in segment IIS6 (see Fig. 8, yellow), so native residues at those positions oppose closed-state inactivation.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of point mutations in segments IS6 and IIS6 on Na+ channel steady-state inactivation. Steady-state inactivation curves for wild-type (), L416A (open circle ), L421C (black-down-triangle ), V424A (down-triangle), M967A (black-square), V974A (), and L983A (black-diamond ) channels are shown. Inactivation curves were measured using 100-ms prepulses to the indicated potentials, followed by a test pulse to 0 mV. Peak test pulse current was plotted as a function of prepulse potential, normalized, and fit with a Boltzmann function: I = 1/(1 + exp((V - V0.5)/k)), where V0.5 is the membrane potential at the half-maximal current and k is a slope factor. Mean V0.5 and k values were determined for each mutant. The curves shown are plots of the Boltzmann function using these mean values.

Point Mutations in Segments IS6 and IIS6 Affect Open-state Fast Inactivation-- Two mutations in segments IS6 and IIS6 caused incomplete inactivation from the open state, resulting in sustained current at the end of a 30-ms depolarization (Fig. 3A). Mutations L421C in segment IS6 and L983A in segment IIS6 exhibited non-inactivating currents, which were ~10 and 16% of the peak current, respectively (Fig. 3B). These sustained Na+ currents were also observed at the end of 100-ms prepulses in measurements of steady-state inactivation (Fig. 2). Other segment IS6 and IIS6 mutations studied did not affect the inactivation from the open state significantly.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of point mutations in segments IS6 and IIS6 on Na+ channel inactivation during depolarizations. A, representative current traces for wild-type, L421C, and L983A channels. Currents were evoked by 30-ms pulses to +5 mV for the wild-type and L421C channels and to 0 mV for the L983A channel from a holding potential of -90 mV. Normalized currents are shown. B, fraction of current that failed to inactivate for wild-type, L421C, and L983A channels. Currents were elicited as described for A. The fraction of non-inactivating current was determined as the current 30 ms after the beginning of the pulse divided by the peak inward current. Error bars indicate S.E. The asterisks indicate significant differences from the wild-type channels as determined by a t test (p < 0.01).

Significant sustained currents produced by mutations L421C and L983A suggest that these two residues might interact either directly or allosterically with the inactivation gate of the Na+ channel, which is formed by the intracellular loop between domains III and IV. Leu421 is positioned near the cytoplasmic end of segment IS6, and Leu983 is positioned at the cytoplasmic end of segment IIS6. Three alanine mutations of residues in the cytoplasmic end of segment IVS6 also caused incomplete inactivation (19, 20). No alanine substitutions disrupted inactivation from the open state in segment IIIS6 (30). Taken together, these data suggest an important role of several hydrophobic residues at the cytoplasmic ends of segments IS6, IIS6, and IVS6 in Na+ channel fast inactivation gating.

Effects of Mutations in Segments IS6 and IIS6 on the Affinity of Inactivated Na+ Channels for Local Anesthetics and Anticonvulsant Drugs-- Voltage-gated Na+ channel pore-blocking drugs, including local anesthetics and antiarrhythmic and anticonvulsant drugs, act by inhibiting ionic currents through the channel. The potency of these drugs stems from their ability to selectively block open and inactivated Na+ channels during abnormal membrane depolarizations and rapid bursts of action potentials that characterize neuronal and cardiac pathologies (47-49). This preferential drug binding to the open and inactivated states rather than the resting channel states can be explained by an allosteric model in which a modulated drug receptor is in a low affinity conformation when the channel is in the resting state and transforms to a high affinity conformation when the channel is opened or inactivated by depolarization (47, 48).

The local anesthetic etidocaine, the anticonvulsant lamotrigine, and its tricyclic congener sipatrigine, formerly termed compound 619C89 (50-52) were previously used to identify specific amino acid residues involved in binding of pore-blocking drugs in transmembrane segments IIIS6 and IVS6 (29-31). In this study, we used etidocaine and sipatrigine for screening of mutants in segments IS6 and IIS6. Etidocaine is used for epidermal, local, and retrobulbar anesthesia. Sipatrigine is being evaluated in clinical trials for the prevention of neuronal toxicity following stroke (52-55). Both of these compounds have higher affinity for inactivated than for resting Na+ channels, like other local anesthetics or anticonvulsant drugs, and also are effective frequency-dependent blockers (29-31, 50). Block of inactivated Na+ channels was determined during a test pulse to 0 mV following a 15-s depolarization to a holding potential at which 70-80% of the Na+ current was inactivated (Fig. 4A, inset, trace c). At this depolarized holding potential (-50 mV for the wild-type Na+ channel), addition of 5 µM etidocaine reduced the Na+ current by 70% (Fig. 4A, inset, trace d). Only 5% of the Na+ current was blocked by the same concentration of etidocaine when the holding potential was -120 mV (Fig. 4A, inset, traces a and b). The apparent dissociation constants for the inactivated state (KI) for the wild-type and mutant Na+ channels were determined from the degree of block at the depolarized potential according to Kuo and Bean (56). Wild-type Na+ channels were inhibited by etidocaine with a KI of ~2 µM under our experimental conditions (30). Mutation I409A caused the largest decrease in affinity for etidocaine of all studied mutations (6-fold increase in KI; p < 0.01) (Fig. 4A). F410A and V424A in segment IS6 also increased the KI of etidocaine, but only by ~2-fold (p <=  0.01) (Fig. 4A). Of all the segment IIS6 mutations studied, only F978A and L983A increased the KI of etidocaine significantly, and their effects were <2-fold (p <=  0.02) (Fig. 4B). Interestingly, none of the mutations studied in segments IS6 and IIS6 had significant effects on the affinity of inactivated channels for sipatrigine (data not shown). Likewise, mutations I409A, F410A, N418A, V424A, F978A, and L983A did not significantly affect the affinity of inactivated channels for the anticonvulsant lamotrigine.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 4.   Affinity of inactivated wild-type and segment IS6 and IIS6 mutant Na+ channels for etidocaine. A: inset, representative current traces for the wild-type channel in the absence (traces a and c) and presence (traces b and d) of 5 µM etidocaine. Traces a and b were measured during a test pulse to 0 mV following a 15-s conditioning pulse to -120 mV. Traces c and d were measured during a test pulse to 0 mV following a 15-s conditioning pulse to -50 mV. A and B: apparent dissociation constants for block of inactivated segment IS6 and IIS6 mutant Na+ channels by etidocaine, respectively. For mutant Na+ channels, the depolarized holding potential was varied so that 70-80% of the channels were inactivated after the 15-s conditioning prepulse. For N418A, activation was shifted positively by ~21 mV, and the slope factor of the activation process was less steep, so a test pulse of +40 mV was used. For L975A, activation was shifted positively by ~17 mV, so the test pulse was +20 mV. The dissociation constant for the inactivated state (KI) for each mutant was calculated according to Kuo and Bean (56) as KI = (1 - h)(Emax/E - 1)[D], where h is the fraction of inactivated channels, Emax is the maximal block that is assumed to be the complete block of the current, and E is the amount of block at the drug concentration ([D]). Error bars indicate S.E. The asterisk indicates a significant difference from the wild-type channel as determined by a t test (p < 0.01).

Effects of Mutations in Segments IS6 and IIS6 on Resting-state Block by Etidocaine-- Block of Na+ channels at a holding potential of -90 mV mainly reflects drug binding to the resting state of the channel (47, 48, 57). To determine whether segment IS6 and IIS6 mutants affected block of resting Na+ channels, we applied 15-ms test pulses from a holding potential of -90 mV in the absence and presence of 100 µM etidocaine. No segment IS6 and IIS6 mutations caused significant decreases in resting affinity for etidocaine (data not shown). Mutations Y415A, M967A, N971A, and V974A significantly increased resting block by etidocaine at a holding potential of -90 mV by 3-, 2-, 6-, and 2-fold, respectively (p < 0.01) (Fig. 5). Because of the preferential state-dependent drug binding to inactivated Na+ channels, it was possible that the apparent increases in affinity were secondary to changes in the voltage dependence of inactivation rather than a reflection of actual changes in resting channel affinity. Mutation Y415A shifted the voltage dependence of inactivation positively by +4 mV, so it opposed inactivation rather than enhancing it; and mutation N971A did not have any effect on the inactivation (see Fig. 8). However, mutations M967A and V974A shifted the voltage dependence of inactivation negatively by -11 mV each (Fig. 2). These negative shifts increased the proportion of inactivated channels at -90 mV, which could have caused the apparent increase in resting-state block for these mutants. Therefore, we examined block at more negative potentials. Consistent with this hypothesis, the affinity of WT channels for etidocaine decreased at more negative holding potentials (Vh), and a greater decrease was observed for V974A and M967A channels. The differences between the WT and mutant channels became insignificant at the most negative potentials (p > 0.05). In contrast, the resting affinities of Y415A and N971A decreased little with further hyperpolarization from -90 mV, and resting affinities for etidocaine were >3-fold greater than that of the WT channel at -120 mV (p < 0.01) (Fig. 5), indicating that these mutations increased the affinity of resting Na+ channels for etidocaine.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5.   Affinity for block of resting Na+ channels by etidocaine. The voltage dependence of the equilibrium dissociation constant (Kr) for block of resting wild-type and mutant Na+ channels by etidocaine is shown. 15-ms test pulses to 0 mV were applied after stepping to the indicated holding potentials (Vh) for 60 s. Kr was calculated according to a single-site binding isotherm: Kr = [D]((1/E- 1), where E represents the fraction of current remaining at the drug concentration ([D]). , WT channel; open circle , Y415A; black-down-triangle , M967A; down-triangle, N971A; black-square, M974A.

Effects of Mutations in Segments IS6 and IIS6 on Frequency-dependent Block by Etidocaine and Sipatrigine-- Frequency-dependent block of Na+ channels by pore-blocking drugs during rapid trains of depolarizing pulses results from preferential binding of the drug to open and inactivated channels and from slower recovery of drug-bound channels between pulses (47, 48). Etidocaine and sipatrigine are strong frequency-dependent blockers (29-31, 50). To determine whether segment IS6 and IIS6 mutants alter frequency-dependent block by etidocaine, we applied 2-Hz trains of 20-ms pulses to 0 mV from a holding potential of -90 mV. For N418A, activation was shifted positively by +21 mV, and channels activated less steeply with voltage. Therefore, a test pulse of +40 mV was used to compensate for these voltage shifts. Mutation I409A significantly reduced frequency-dependent block by etidocaine, and frequency-dependent block was almost completely abolished by mutation N418A (Fig. 6). No other segment IS6 mutations affected frequency-dependent block by etidocaine, and it was not significantly affected by any segment IIS6 mutation. No segment IS6 or IIS6 mutation had a significant effect on frequency-dependent block by sipatrigine (data not shown).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6.   Frequency-dependent block of wild-type and mutant Na+ channels by etidocaine. Frequency-dependent block of wild-type and mutant Na+ channels by 100 µM etidocaine is shown. The cells were held at -90 mV and stimulated by 20-ms test pulses to 0 mV in 2-Hz pulse trains. For N418A, activation was shifted positively by ~21 mV, and the slope factor of the activation process was less steep. Therefore, a test pulse of +40 mV was used. The peak current amplitude in response to each pulse in the presence of the drug was measured, normalized with respect to peak current for the corresponding pulse before drug application, and plotted versus the pulse number.

Effect of Mutations I409A and N418A on Recovery of Na+ Channels from Inactivated-state Etidocaine Block-- We studied recovery of etidocaine-blocked inactivated Na+ channels to the resting state for mutations I409A and N418A, which significantly affected voltage- and frequency-dependent block of Na+ channels by etidocaine. We measured the rate of recovery by applying a 500-ms conditioning prepulse to 0 mV (to +40 mV for N418A; see above) to produce drug block of inactivated channels, followed by a recovery interval of variable duration and a test pulse to 0 mV (to +40 mV for N418A). Recovery under control conditions followed a double-exponential time course with fast (tau fast) and slow (tau slow) time constants (Fig. 7, A-C, closed circles). The wild-type channels recovered with tau fast = 5.2 ± 0.8 ms and tau slow = 134 ± 12 ms (Fig. 7A). I409A recovered with tau fast = 4.5 ± 0.2 ms and tau slow = 143 ± 12 ms (Fig. 7B), which were similar to the wild-type kinetics. In contrast, N418A recovered with tau fast = 1.2 ± 0.2 ms or ~4-fold faster than the wild-type channels and with tau slow = 337 ± 28 ms or at least 2.5-fold slower than the wild-type channels (Fig. 7C). This time constant is a minimum estimate because only ~80% of the N418A current had recovered after 4 s (Fig. 7C), whereas 100% of the WT current had recovered after 400 ms (Fig. 7A). These data indicate that mutation N418A is characterized by a slow inactivated state with far slower recovery kinetics than the WT channel. Alanine mutation of the homologous residue in the rat skeletal muscle Nav1.4 channel, Asn434, also enhances slow inactivation (58). Thus, the native asparagine in segment IS6 is critical for setting slow inactivation properties of Na+ channels.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 7.   Recovery of the wild-type and mutant Na+ channels from block of inactivated channels by etidocaine. A-C, representative time courses of Na+ channel recovery from inactivation under control conditions () and in the presence of 100 µM etidocaine (open circle ) for wild-type (A), I409A (B), and N418A (C) channels. Recovery was measured using a 500-ms conditioning pulse to 0 mV (to +40 mV for N418A), followed by a recovery interval of the indicated duration (1.5-4000 ms) at -90 mV, followed by a test pulse to 0 mV (to +40 mV for N418A). The peak test pulse current was divided by the peak conditioning pulse current and plotted against the recovery time interval. The curves are least-squares fits of a two-exponential function to the data.

In the presence of 100 µM etidocaine, the fast time constant reflects recovery from inactivation of the small fraction of channels that were not blocked during the conditioning prepulse. The slow time constant reflects slow dissociation of the drug from the channels that were blocked during the conditioning prepulse (tau drug). For the wild-type channels, tau drug was 2.2 ± 0.2 s (Fig. 7A). For I409A, tau drug was 1.7 ± 0.1 s, not significantly different from the tau drug for the wild-type channels (p > 0.05) (Fig. 7B). In contrast, N418A recovered with tau drug = 0.32 ± 0.03 s (p < 0.01) (Fig. 7C), 7-fold faster than the tau drug for the wild-type channels. Furthermore, in the presence of 100 µM etidocaine, N418A reached 100% recovery after ~2 s (Fig. 7C), whereas the control N418A channel had only recovered to ~70% of its initial level by 4 s (Fig. 7A). The dramatically faster recovery of the drug-bound channel indicates that etidocaine impeded entry into the slow inactivated state. The faster recovery compared with the WT channel recovery suggests a lower affinity of the closed inactivated N418A channel for etidocaine compared with the affinity of the WT channels. This faster dissociation of etidocaine from N418A contributes to the reduction in frequency-dependent block of this mutant by etidocaine (Fig. 6). In contrast, the reduction in frequency-dependent block of I409A must be primarily caused by the reduced affinity of this mutant for etidocaine because the mutation has no effect on recovery from etidocaine block.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Role of Amino Acid Residues in the S6 Transmembrane Segments in Na+ Channel Activation-- Our present results on mutations in segments IS6 and IIS6 and previously published data on mutations in segments IIIS6 and IVS6 (20, 30) are summarized in Fig. 8. We used multiple sequence alignment of all four S6 segments to produce a position-dependent plot of shifts in the voltage dependence of activation gating (Fig. 8, Activation Shift) and shifts in the slope factor (k) of the activation process (Slope Effect). This plot demonstrates that a number of mutations in the extracellular part of the S6 segments caused small shifts in the voltage dependence of activation (Fig. 8, Activation Shift, positions 1-8). Mutations of residues located in the middle part of the S6 segments did not produce significant effects on the voltage dependence of activation (Fig. 8, Activation Shift, positions 9-12). Mutations in the intracellular part of the S6 segments had strong effects on the voltage dependence of activation gating (Fig. 8, Activation Shift, positions 13-21). Therefore, we suggest that the intracellular part of each of the pore-lining S6 segments plays an important role in the conformational changes leading to the opening of the Na+ channel. Mutations of residues at positions 13 (L975A in segment IIS6 and V1768A in segment IVS6), 14 (N418A in segment IS6 and N1769A in segment IVS6), and 17 (I1469A in segment IIIS6 and I1772A in segment IVS6) (Fig. 8, Activation Shift) caused striking positive shifts in the voltage dependence of activation. The positive shifts in activation gating indicate that the native residues at these positions make interactions that stabilize the open state of the channel. Mutations at positions 14 (N418A in segment IS6, N1466A in segment IIIS6, and N1769A in segment IVS6), 15 (L1467A in segment IIIS6), and 17 (L421C in segment IS6 and I1772A in segment IVS6) also significantly decreased the steepness of the voltage dependence of the activation process (Fig. 8, Slope Effect). All of the native residues at these positions are proposed to face away from the pore lumen of the Na+ channel (Fig. 9). Therefore, the effects of mutations of these residues on the slope of the activation process suggest that these residues may interact with the voltage-sensing S4 segments of the Na+ channel and alter their transmembrane movement during activation, resulting in reduced and shifted transmembrane charge movement.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 8.   Summary of effect of mutations in all four S6 segments on activation and inactivation gating. Left panel, vertical representation of amino acid sequence alignment of S6 segments in domains I-IV (see "Experimental Procedures"). Segment IS6 residues are from Phe405 to Ala425. Segment IIS6 residues are from Phe963 to Leu983. Segment IIIS6 residues are from Phe1453 to Ile1473. Segment IVS6 residues are from Phe1756 to Leu1776. Activation Shift, the half-maximal activation voltage (V0.5) of S6 segment mutants from domains I-IV compared with that of the wild-type Na+ channels. The histogram shows the differences in voltage for the half-maximal activation of the wild-type and mutant Na+ channels. Mean V0.5 values were obtained from Boltzmann fits of normalized conductance versus voltage plots as described in the legend to Fig. 1. Bars are colored red for the corresponding mutations in domain I, yellow for mutations in domain II, green for mutations in domain III, and blue for mutations in domain IV. The S6 segments were aligned as described above. Slope Effect, the slope factor of the activation process (k) of the S6 segment mutants from domains I-IV compared with that of the wild-type Na+ channels. The histogram shows the differences in k values for the wild-type and mutant Na+ channels. Mean k values were obtained from Boltzmann fits of normalized conductance versus voltage plots as described in the legend to Fig. 1. Inactivation Shift, the half-maximal inactivation voltage (V0.5) of S6 segment mutants from domains I-IV compared with that of the wild-type Na+ channels. The histogram shows the differences in voltage for the half-maximal inactivation of the wild-type and mutant Na+ channels. Mean V0.5 values were obtained from Boltzmann fits of normalized current versus voltage plots as described in the legend to Fig. 2.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 9.   Model of etidocaine binding to transmembrane segments IS6, IIIS6, and IVS6 of the rat brain Nav1.2 channel. A, three-dimensional model (see "Experimental Procedures") of the proposed orientation of amino acid residues within the Na+ channel pore with respect to the local anesthetic etidocaine. Only transmembrane segments IS6 (red), IIIS6 (green), and IVS6 (blue) are shown. Etidocaine (yellow) is shown in stick representation. Residues important in etidocaine binding are shown in space-filling representation. This figure was prepared with MOLSCRIPT and RASTER-3D (70, 71). B, alpha -helical representation showing the axial positions of mutations that caused reduction in the affinity of etidocaine (ETID) for the inactivated Na+ channels.

The position-dependent profile of shifts produced by mutations in the intracellular part of the S6 segments (Fig. 8, Activation Shift, positions 13-20) is also consistent with an alpha -helical structure of the S6 segments and with a rotational motion of this helix during channel activation. Movements of an intracellular part of the pore-forming S6 segments in the voltage-dependent K+ channels and the corresponding M2 segments in KcsA channels have been proposed to regulate channel opening and closing (59-65). Rotational motion of the pore-forming M2 segments in the KcsA channels about their helical axis during activation gating has been detected using EPR (63, 65). By comparing the structure of KcsA with a newly determined structure of a Ca2+-activated K+ channel from Methanobacterium thermoautotrophicum (MthK), Jiang et al. (60) proposed that the M2 segments rotate and move laterally and outward, resulting in a 12-Å opening at the intracellular aspect of the pore. This movement hinges on a critical glycine residue located approximately halfway through the M2 helix, which is conserved in S6 segments I-III of voltage-gated sodium channels. Our results suggest that the intracellular part of the S6 segments in Na+ channels also may be involved in rotational and translational movements during channel opening.

Role of Amino Acid Residues in the S6 Transmembrane Segments in Na+ Channel Inactivation-- The majority of mutations in segment IS6 caused positive shifts in the voltage dependence of inactivation (Fig. 8, Inactivation Shift, red bars), indicating that the native residues at those positions favor inactivation from the closed state. In contrast, mutations in segments IIS6, IIIS6, and IVS6 produced negative shifts in the voltage dependence of inactivation (Fig. 8, Inactivation Shift, yellow, green, and blue bars), indicating that the native residues at those positions oppose inactivation from the closed state. Large shifts were produced by alanine mutations in the intracellular half of segment IIIS6 (Fig. 8, Inactivation Shift, positions 13-21, green bars), suggesting that the intracellular half of segment IIIS6 plays an important role in a conformational change during the transition from the closed to the closed inactivated state. Mutations of several residues in the extracellular half of the S6 segments (Fig. 8, Inactivation Shift, positions 5-7) produced strong negative shifts in the voltage dependence of inactivation.

Role of Amino Acid Residues at the Intracellular End of Segments IS6, IIS6, and IVS6 in Na+ Channel Open-state Inactivation-- Fast inactivation of Na+ channels from the open state is thought to occur by binding of an intracellular inactivation gate formed by the loop between domains III and IV to regions around the channel pore through hydrophobic interactions (8, 66-68). Previous studies have demonstrated that mutation to alanine of three hydrophobic residues at the intracellular end of segment IVS6 strongly disrupts open-state inactivation (19, 20), whereas none of the alanine mutations in segment IIIS6 disrupt open-state inactivation (30). Our present results for transmembrane segments IS6 and IIS6 demonstrate that mutations L421C in segment IS6 and L983A in segment IIS6 disrupted inactivation from the open state and caused non-inactivating Na+ currents. Thus, amino acid residues at the intracellular end of segments IS6, IIS6, and IVS6, but not segment IIIS6, are important for closure of the Na+ channel fast inactivation gate. These are highly specific interactions because >80 other mutations in the S6 segments did not cause non-inactivating Na+ currents.

Alignment of the four S6 segments of the Na+ channel places Leu421, Leu983, and Val1774, the amino acid residues at which alanine substitution greatly impairs open-state inactivation, at positions 17, 21, and 19 of the S6 helices, respectively (Fig. 8). Amino acid residues in equivalent positions are located at the point where the M2 helices cross each other in the closed three-dimensional structure of the KcsA channel (6) and are just beyond the most outward amino acids in the S6 segments that are accessible to methane thiosulfonate reagents applied from the cytoplasmic surface to the closed conformation of the Shaker K+ channel (64). The equivalent amino acid residues in KcsA are thought to move laterally to widen the vestibule of the pore as the channel activates (60, 65, 69). An analogous movement in the sodium channel S6 segments would move the native amino acids near the bundle crossing in the closed sodium channel laterally and reveal newly accessible side chain moieties that form part of the receptor for the inactivation gate and that stabilize the inactivated state. Thus, the specific set of amino acid residues at which alanine substitution disrupts inactivation is likely to become accessible upon channel activation and present a hydrophobic surface to which the IFM motif of the inactivation gate can dock.

Receptor Site for Local Anesthetics and Antiarrhythmic and Anticonvulsant Drugs within Pore-forming S6 Segments of the Na+ Channel-- Our previous data for transmembrane segments IIIS6 (30) and IVS6 (29) and our present results on segments IS6 and IIS6 give a more complete view of the molecular determinants of the receptor site for the local anesthetic etidocaine and related pore-blocking drugs. Mutations F1764A and Y1771A in segment IVS6 reduced the affinity of inactivated Na+ channels for etidocaine by 130- and 35-fold, respectively (29). Mutation I1760A, also in segment IVS6, did not have a significant effect on etidocaine affinity, but accelerated the off-rate of etidocaine from the closed channels at negative potentials (29). Apparently, mutation I1760A created another pathway for etidocaine to escape from its binding site (29, 33). Mutations L1465A, N1466A, and I1469A in segment IIIS6 caused 6-, 8-, and 7-fold reductions in the inactivated-state affinity, respectively (30). Of all the mutations studied in segments IS6 and IIS6, only mutation I409A in segment IS6 decreased inactivated-state block by etidocaine by as much as 6-fold. Thus, we propose that Ile409 in segment IS6 faces the pore lumen in the inactivated state of the Na+ channel, along with the amino acid residues in segments IIIS6 and IVS6 that bind local anesthetics (Fig. 9). None of the segment IIS6 mutations studied had any significant effect on the inactivated-state affinity of etidocaine or had an effect on frequency-dependent block by this drug. Therefore, we cannot define any pore-facing residue(s) in segment IIS6.

Based on the available data for all four S6 segments of the Na+ channel, we propose a molecular model for the individual amino acid residues in transmembrane segments IS6, IIIS6, and IVS6 that form the local anesthetic receptor site (Fig. 9). In addition to our results, site-directed mutagenesis studies of Phe1710 and Tyr1717 in segment IVS6 of the rat brain Nav1.3 channel (homologous to Phe1764 and Tyr1771, respectively, in the rat brain Nav1.2 channel) introduced mutations varying in size, hydrophobicity, and aromaticity and demonstrated in more detail how these residues influence local anesthetic drug binding (38). Block of open and inactivated channels by the local anesthetic tetracaine required an aromatic residue at position 1710 of the Nav1.3 channel. This phenylalanine residue is positioned in the middle of segment IVS6 (Fig. 9) and could stabilize the drug binding to the open or inactivated states by either cation-pi or aromatic-aromatic interactions between the aromatic side chain of the amino acid and charged or aromatic moieties on the drug molecule (38). Therefore, Nav1.3 channel Phe1710 (homologous to Nav1.2 channel Phe1764) has been proposed to contribute directly to the local anesthetic receptor site (38). In contrast, effects on drug action of mutations of Nav1.3 channel Tyr1717 (homologous to Nav1.2 channel Tyr1771) were not well correlated with the size, hydrophobicity, or aromaticity of the substituted amino acid. Further studies are necessary to determine whether Ile409 in segment IS6 and Leu1465, Asn1466, and Ile1469 in segment IIIS6 contribute directly to the local anesthetic receptor site, but this is the most straightforward conclusion from the experimental results presented here.

None of the segment IS6 or IIS6 mutations studied had any significant effect on inactivated-state affinity or frequency-dependent block by sipatrigine, suggesting that its binding contacts are all in segments IIIS6 and IVS6. Similarly, the mutations in segment IS6 that had effects on etidocaine binding and block had no effect on block by the anticonvulsant lamotrigine. Therefore, our results to date suggest that amino acid residues in segments IIIS6 and IVS6 form the receptor site for these anticonvulsant drugs, with little participation of amino acid residues in segment IS6 or IIS6. These different molecular interactions may underlie the different kinetic effects and therapeutic uses of the anticonvulsant and local anesthetic Na+ channel-blocking drugs.

The lateral movement of M2 segments and the resulting large intracellular opening proposed to occur as KcsA/MthK open channels (6, 60) have important implications for drug block of voltage-gated sodium channels. First, the intracellular opening is critical for allowing rapid access of large blocking compounds to their binding sites within the pore. Second, the glycine responsible for S6 segment flexibility in channel opening is absent in segment IVS6, the segment where alanine substitutions cause the most marked state-dependent disruptions in drug block. The lack of a glycine suggests that segment IVS6 may be less mobile and therefore may maintain an angled disposition relative to the pore axis or undergo a smaller conformational change during activation. The different gating movement of segment IVS6 may contribute to its primary role in drug binding. State-dependent drug block may result from the small movement of segment IVS6 or from larger movements of other S6 segments, perhaps relieving steric hindrance near critical binding residues such as Phe1764 and Tyr1771 in segment IVS6.

    FOOTNOTES

* This work was supported by Research Grant R-01 N515751 from the National Institutes of Health (to W. A. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Pharmacology, P. O. Box 357280, Seattle, WA 98195-7280. Tel.: 206-543-1925; Fax: 206-543-3882; E-mail: wcatt@u.washington.edu.

Published, JBC Papers in Press, July 18, 2002, DOI 10.1074/jbc.M206126200

    ABBREVIATIONS

The abbreviation used is: WT, wild-type.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Hille, B. (2001) Ionic Channels of Excitable Membranes , 3rd Ed. , Sinauer Associates, Inc., Sunderland, MA
2. Catterall, W. A. (2000) Neuron 26, 13-25[CrossRef][Medline] [Order article via Infotrieve]
3. Cohen, S. A., and Barchi, R. L. (1993) Int. Rev. Cytol. 137C, 55-103[Medline] [Order article via Infotrieve]
4. Fozzard, H. A., and Hanck, D. A. (1996) Physiol. Rev. 76, 887-926[Abstract/Free Full Text]
5. Marban, E., Yamagishi, T., and Tomaselli, G. (1998) J. Physiol. (Lond.) 508, 647-657[Abstract/Free Full Text]
6. Doyle, D. A., Cabral, J. M., Pfuetzner, R. A., Kuo, A. L., Gulbis, J. M., Cohen, S. L., Chait, B. T., and MacKinnon, R. (1998) Science 280, 69-77[Abstract/Free Full Text]
7. Hodgkin, A. L., and Huxley, A. F. (1952) J. Physiol. (Lond.) 117, 500-544
8. Armstrong, C. M. (1981) Physiol. Rev. 61, 644-683[Free Full Text]
9. Catterall, W. A. (1986) Trends Neurosci. 9, 7-10
10. Guy, H. R., and Seetharamulu, P. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 508-512[Abstract/Free Full Text]
11. Stühmer, W., Conti, F., Suzuki, H., Wang, X. D., Noda, M., Yahagi, N., Kubo, H., and Numa, S. (1989) Nature 339, 597-603[CrossRef][Medline] [Order article via Infotrieve]
12. Kontis, K. J., Rounaghi, A., and Goldin, A. L. (1997) J. Gen. Physiol. 110, 391-401[Abstract/Free Full Text]
13. Yang, N., and Horn, R. (1995) Neuron 15, 213-218[CrossRef][Medline] [Order article via Infotrieve]
14. Cha, A., Ruben, P. C., George, A. L., Jr., Fujimoto, E., and Bezanilla, F. (1999) Neuron 22, 73-87[CrossRef][Medline] [Order article via Infotrieve]
15. Yang, N., George, A. L., Jr., and Horn, R. (1996) Neuron 16, 113-122[CrossRef][Medline] [Order article via Infotrieve]
16. Vassilev, P. M., Scheuer, T., and Catterall, W. A. (1988) Science 241, 1658-1661[Abstract/Free Full Text]
17. Vassilev, P., Scheuer, T., and Catterall, W. A. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8147-8151[Abstract/Free Full Text]
18. West, J. W., Patton, D. E., Scheuer, T., Wang, Y., Goldin, A. L., and Catterall, W. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10910-10914[Abstract/Free Full Text]
19. McPhee, J. C., Ragsdale, D. S., Scheuer, T., and Catterall, W. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12346-12350[Abstract/Free Full Text]
20. McPhee, J. C., Ragsdale, D. S., Scheuer, T., and Catterall, W. A. (1995) J. Biol. Chem. 270, 12025-12034[Abstract/Free Full Text]
21. Smith, M. R., and Goldin, A. L. (1997) Biophys. J. 73, 1885-1895[Medline] [Order article via Infotrieve]
22. Lerche, H., Peter, W., Fleischhauer, R., PikaHartlaub, U., Malina, T., Mitrovic, N., and Lehmann-Horn, F. (1997) J. Physiol. (Lond.) 505, 345-352[Abstract/Free Full Text]
23. Filatov, G. N., Nguyen, T. P., Kraner, S. D., and Barchi, R. L. (1998) J. Gen. Physiol. 111, 703-715[Abstract/Free Full Text]
24. McPhee, J. C., Ragsdale, D. S., Scheuer, T., and Catterall, W. A. (1998) J. Biol. Chem. 273, 1121-1129[Abstract/Free Full Text]
25. Tang, L., Chehab, N., Wieland, S. J., and Kallen, R. G. (1998) J. Gen. Physiol. 111, 639-652[Abstract/Free Full Text]
26. Chen, L. Q., Santarelli, V., Horn, R., and Kallen, R. G. (1996) J. Gen. Physiol. 108, 549-556[Abstract/Free Full Text]
27. Rogers, J. C., Qu, Y., Tanada, T. N., Scheuer, T., and Catterall, W. A. (1996) J. Biol. Chem. 271, 15950-15962[Abstract/Free Full Text]
28. Sheets, M. F., Kyle, J. W., Kallen, R. G., and Hanck, D. A. (1999) Biophys. J. 77, 747-757[Medline] [Order article via Infotrieve]
29. Ragsdale, D. S., McPhee, J. C., Scheuer, T., and Catterall, W. A. (1994) Science 265, 1724-1728[Abstract/Free Full Text]
30. Yarov-Yarovoy, V., Brown, J., Sharp, E. M., Clare, J. J., Scheuer, T., and Catterall, W. A. (2001) J. Biol. Chem. 276, 20-27[Abstract/Free Full Text]
31. Liu, G., Scheuer, T., and Catterall, W. A. (1998) Biophys. J. 74, A399 (abstr.)
32. Goldin, A. L., Barchi, R. L., Caldwell, J. H., Hofmann, F., Howe, J. R., Hunter, J. C., Kallen, R. G., Mandel, G., Meisler, M. H., Netter, Y. B., Noda, M., Tamkun, M. M., Waxman, S. G., Wood, J. N., and Catterall, W. A. (2000) Neuron 28, 365-368[CrossRef][Medline] [Order article via Infotrieve]
33. Qu, Y., Rogers, J., Tanada, T., Scheuer, T., and Catterall, W. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11839-11843[Abstract/Free Full Text]
34. Ragsdale, D. S., McPhee, J. C., Scheuer, T., and Catterall, W. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9270-9275[Abstract/Free Full Text]
35. Wang, G. K., Quan, C., and Wang, S. (1998) Pfluegers Arch. Eur. J. Physiol. 435, 293-302[CrossRef][Medline] [Order article via Infotrieve]
36. Wright, S. N., Wang, S. Y., and Wang, G. K. (1998) Mol. Pharmacol. 54, 733-739[Abstract/Free Full Text]
37. Weiser, T., Qu, Y., Catterall, W. A., and Scheuer, T. (1999) Mol. Pharmacol. 56, 1238-1244[Abstract/Free Full Text]
38. Li, H. L., Galue, A., Meadows, L., and Ragsdale, D. S. (1999) Mol. Pharmacol. 55, 134-141[Abstract/Free Full Text]
39. Carter, A. J., Grauert, M., Pschorn, U., Bechtel, W. D., Bartmann-Lindholm, C., Qu, Y., Scheuer, T., Catterall, W. A., and Weiser, T. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4944-4949[Abstract/Free Full Text]
40. Wang, S. Y., Nau, C., and Wang, G. K. (2000) Biophys. J. 79, 1379-1387[Medline] [Order article via Infotrieve]
41. Wang, G. K., Quan, C., and Wang, S. Y. (1998) Mol. Pharmacol. 54, 389-396[Abstract/Free Full Text]
42. Jeanmougin, F., Thompson, J. D., Gouy, M., Higgins, D. G., and Gibson, T. J. (1998) Trends Biochem. Sci. 23, 403-405[CrossRef][Medline] [Order article via Infotrieve]
43. Penzotti, J. L., Fozzard, H. A., Lipkind, G. M., and Dudley, S. C., Jr. (1998) Biophys. J. 75, 2647-2657[Medline] [Order article via Infotrieve]
44. Li, R. A., Ennis, I. L., French, R. J., Dudley, S. C., Jr., Tomaselli, G. F., and Marban, E. (2001) J. Biol. Chem. 276, 11072-11077[Abstract/Free Full Text]
45. Richardson, J. S. (1981) Adv. Protein Chem. 34, 167-339[Medline] [Order article via Infotrieve]
46. Blaber, M., Zhang, X. J., and Matthews, B. W. (1993) Science 260, 1637-1640[Abstract/Free Full Text]
47. Hille, B. (1977) J. Gen. Physiol. 69, 497-515[Abstract/Free Full Text]
48. Hondeghem, L. M., and Katzung, B. G. (1977) Biochim. Biophys. Acta 472, 373-398[Medline] [Order article via Infotrieve]
49. Catterall, W. A. (1987) Trends Pharmacol. Sci. 8, 57-65[CrossRef]
50. Xie, X. M., and Garthwaite, J. (1996) Neuroscience 73, 951-962[CrossRef][Medline] [Order article via Infotrieve]
51. Calabresi, P., Stefani, A., Marfia, G. A., Hainsworth, A. H., Centonze, D., Saulle, E., Spadoni, F., Leach, M. J., Giacomini, P., and Bernardi, G. (2000) Exp. Neurol. 162, 171-179[CrossRef][Medline] [Order article via Infotrieve]
52. Leach, M. J., Swan, J. H., Eisenthal, D., Dopson, M., and Nobbs, M. (1993) Stroke 24, 1063-1067[Abstract/Free Full Text]
53. Muir, K. W., Holzapfel, L., and Lees, K. R. (2000) Cerebrovasc. Dis. 10, 431-436[CrossRef][Medline] [Order article via Infotrieve]
54. Muir, K. W., Hamilton, S. J., Lunnon, M. W., Hobbiger, S., and Lees, K. R. (1998) Cerebrovasc. Dis. 8, 31-37[CrossRef][Medline] [Order article via Infotrieve]
55. Muir, K. W., Lees, K. R., Hamilton, S. J., George, C. F., Hobbiger, S. F., and Lunnon, M. W. (1995) Ann. N. Y. Acad. Sci. 765, 328-329[CrossRef][Medline] [Order article via Infotrieve]
56. Kuo, C. C., and Bean, B. P. (1994) Mol. Pharmacol. 46, 716-725[Abstract]
57. Butterworth, J. F., and Strichartz, G. R. (1990) Anesthesiology 72, 711-734[Medline] [Order article via Infotrieve]
58. Wang, S. Y., and Wang, G. K. (1997) Biophys. J. 72, 1633-1640[Medline] [Order article via Infotrieve]
59. Liu, Y., Holmgren, M., Jurman, M. E., and Yellen, G. (1997) Neuron 19, 175-184[CrossRef][Medline] [Order article via Infotrieve]
60. Jiang, Y., Lee, A., Chen, J., Cadene, M., Chait, B. T., and MacKinnon, R. (2002) Nature 417, 523-526[CrossRef][Medline] [Order article via Infotrieve]
61. Perozo, E., Cortes, D. M., and Cuello, L. G. (1998) Nat. Struct. Biol. 5, 459-469[CrossRef][Medline] [Order article via Infotrieve]
62. Holmgren, M., Shin, S. H., and Yellen, G. (1998) Neuron 21, 617-621[CrossRef][Medline] [Order article via Infotrieve]
63. Perozo, E., Cortes, D. M., and Cuello, L. G. (1999) Science 285, 73-78[Abstract/Free Full Text]
64. del Camino, D., Holmgren, M., Liu, Y., and Yellen, G. (2000) Nature 403, 321-325[CrossRef][Medline] [Order article via Infotrieve]
65. Liu, Y. S., Sompornpisut, P., and Perozo, E. (2001) Nat. Struct. Biol. 8, 883-887[CrossRef][Medline] [Order article via Infotrieve]
66. Armstrong, C. M., and Bezanilla, F. (1977) J. Gen. Physiol. 70, 567-590[Abstract/Free Full Text]
67. Zagotta, W. N., and Aldrich, R. W. (1990) J. Gen. Physiol. 95, 29-60[Abstract/Free Full Text]
68. Hoshi, T., Zagotta, W. N., and Aldrich, R. W. (1991) Neuron 7, 547-556[CrossRef][Medline] [Order article via Infotrieve]
69. Kong, Y., Shen, Y., Warth, T. E., and Ma, J. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 5999-6004[Abstract/Free Full Text]
70. Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950[CrossRef]
71. Merritt, E. A., and Bacon, D. J. (1997) Methods Enzymol. 277, 505-524[Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
L. E. Browne, F. E. Blaney, S. P. Yusaf, J. J. Clare, and D. Wray
Structural Determinants of Drugs Acting on the Nav1.8 Channel
J. Biol. Chem., April 17, 2009; 284(16): 10523 - 10536.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
Y. Muroi and B. Chanda
Local Anesthetics Disrupt Energetic Coupling between the Voltage-sensing Segments of a Sodium Channel
J. Gen. Physiol., December 29, 2008; 133(1): 1 - 15.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
I. Bruhova, D. B. Tikhonov, and B. S. Zhorov
Access and Binding of Local Anesthetics in the Closed Sodium Channel
Mol. Pharmacol., October 1, 2008; 74(4): 1033 - 1045.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. M. Barajas-Martinez, D. Hu, J. M. Cordeiro, Y. Wu, R. J. Kovacs, H. Meltser, H. Kui, B. Elena, R. Brugada, C. Antzelevitch, et al.
Lidocaine-Induced Brugada Syndrome Phenotype Linked to a Novel Double Mutation in the Cardiac Sodium Channel
Circ. Res., August 15, 2008; 103(4): 396 - 404.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. A. Ahern, A. L. Eastwood, D. A. Dougherty, and R. Horn
Electrostatic Contributions of Aromatic Residues in the Local Anesthetic Receptor of Voltage-Gated Sodium Channels
Circ. Res., January 4, 2008; 102(1): 86 - 94.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
J. H. Chancey, P. E. Shockett, and J. P. O'Reilly
Relative resistance to slow inactivation of human cardiac Na+ channel hNav1.5 is reversed by lysine or glutamine substitution at V930 in D2-S6
Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1895 - C1905.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
K. Susankova, R. Ettrich, L. Vyklicky, J. Teisinger, and V. Vlachova
Contribution of the Putative Inner-Pore Region to the Gating of the Transient Receptor Potential Vanilloid Subtype 1 Channel (TRPV1)
J. Neurosci., July 11, 2007; 27(28): 7578 - 7585.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
M. F. Sheets and D. A. Hanck
Outward stabilization of the S4 segments in domains III and IV enhances lidocaine block of sodium channels
J. Physiol., July 1, 2007; 582(1): 317 - 334.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
M. M. McNulty, G. B. Edgerton, R. D. Shah, D. A. Hanck, H. A. Fozzard, and G. M. Lipkind
Charge at the lidocaine binding site residue Phe-1759 affects permeation in human cardiac voltage-gated sodium channels
J. Physiol., June 1, 2007; 581(2): 741 - 755.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. J. Jones, Y. Wang, M. D. Smith, N. J. Hargus, H. S. Eidam, H. S. White, J. Kapur, M. L. Brown, and M. K. Patel
Hydroxyamide Analogs of Propofol Exhibit State-Dependent Block of Sodium Channels in Hippocampal Neurons: Implications for Anticonvulsant Activity
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 828 - 836.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Raybaud, Y. Dodier, P. Bissonnette, M. Simoes, D. G. Bichet, R. Sauve, and L. Parent
The Role of the GX9GX3G Motif in the Gating of High Voltage-activated Ca2+ Channels
J. Biol. Chem., December 22, 2006; 281(51): 39424 - 39436.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. M. McNulty, J. W. Kyle, G. M. Lipkind, and D. A. Hanck
An Inner Pore Residue (Asn406) in the Nav1.5 Channel Controls Slow Inactivation and Enhances Mibefradil Block to T-Type Ca2+ Channel Levels
Mol. Pharmacol., November 1, 2006; 70(5): 1514 - 1523.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. A. M. Smith, S. M. Amagasu, J. Hembrador, S. Axt, R. Chang, T. Church, C. Gee, J. R. Jacobsen, T. Jenkins, E. Kaufman, et al.
Evidence for a Multivalent Interaction of Symmetrical, N-Linked, Lidocaine Dimers with Voltage-Gated Na+ Channels
Mol. Pharmacol., March 1, 2006; 69(3): 921 - 931.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. M. Lipkind and H. A. Fozzard
Molecular Modeling of Local Anesthetic Drug Binding by Voltage-Gated Sodium Channels
Mol. Pharmacol., December 1, 2005; 68(6): 1611 - 1622.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
W. Ulbricht
Sodium Channel Inactivation: Molecular Determinants and Modulation
Physiol Rev, October 1, 2005; 85(4): 1271 - 1301.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
S. Ding, L. Ingleby, C. A. Ahern, and R. Horn
Investigating the Putative Glycine Hinge in Shaker Potassium Channel
J. Gen. Physiol., August 29, 2005; 126(3): 213 - 226.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Y. Tsang, R. G. Tsushima, G. F. Tomaselli, R. A. Li, and P. H. Backx
A Multifunctional Aromatic Residue in the External Pore Vestibule of Na+ Channels Contributes to the Local Anesthetic Receptor
Mol. Pharmacol., February 1, 2005; 67(2): 424 - 434.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Zhao, T. Scheuer, and W. A. Catterall
Reversed voltage-dependent gating of a bacterial sodium channel with proline substitutions in the S6 transmembrane segment
PNAS, December 21, 2004; 101(51): 17873 - 17878.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
A. Sunami, A. Tracey, I. W Glaaser, G. M Lipkind, D. A Hanck, and H. A Fozzard
Accessibility of mid-segment domain IV S6 residues of the voltage-gated Na+ channel to methanethiosulfonate reagents
J. Physiol., December 1, 2004; 561(2): 403 - 413.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
S.-Y. Wang, J. Mitchell, E. Moczydlowski, and G. K. Wang
Block of Inactivation-deficient Na+ Channels by Local Anesthetics in Stably Transfected Mammalian Cells: Evidence for Drug Binding Along the Activation Pathway
J. Gen. Physiol., November 29, 2004; 124(6): 691 - 701.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
W. Sandtner, J. Szendroedi, T. Zarrabi, E. Zebedin, K. Hilber, I. Glaaser, H. A. Fozzard, S. C. Dudley, and H. Todt
Lidocaine: A Foot in the Door of the Inner Vestibule Prevents Ultra-Slow Inactivation of a Voltage-Gated Sodium Channel
Mol. Pharmacol., September 1, 2004; 66(3): 648 - 657.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Z. Li, K. Migita, D. S. K. Samways, M. M. Voigt, and T. M. Egan
Gain and Loss of Channel Function by Alanine Substitutions in the Transmembrane Segments of the Rat ATP-Gated P2X2 Receptor
J. Neurosci., August 18, 2004; 24(33): 7378 - 7386.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. De Luca, S. Talon, M. De Bellis, J.-F. Desaphy, G. Lentini, F. Corbo, A. Scilimati, C. Franchini, V. Tortorella, and D. C. Camerino
Optimal Requirements for High Affinity and Use-Dependent Block of Skeletal Muscle Sodium Channel by N-Benzyl Analogs of Tocainide-Like Compounds
Mol. Pharmacol., October 1, 2003; 64(4): 932 - 945.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. Kondratiev and G. F. Tomaselli
Altered Gating and Local Anesthetic Block Mediated by Residues in the I-S6 and II-S6 Transmembrane Segments of Voltage-Dependent Na+ Channels
Mol. Pharmacol., September 1, 2003; 64(3): 741 - 752.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
G. K. Wang, C. Russell, and S.-Y. Wang
State-dependent Block of Wild-type and Inactivation-deficient Na+ Channels by Flecainide
J. Gen. Physiol., August 25, 2003; 122(3): 365 - 374.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
W. Ouyang, G. Wang, and H. C. Hemmings Jr
Isoflurane and Propofol Inhibit Voltage-Gated Sodium Channels in Isolated Rat Neurohypophysial Nerve Terminals
Mol. Pharmacol., August 1, 2003; 64(2): 373 - 381.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Nau, S.-Y. Wang, and G. K. Wang
Point Mutations at L1280 in Nav1.4 Channel D3-S6 Modulate Binding Affinity and Stereoselectivity of Bupivacaine Enantiomers
Mol. Pharmacol., June 1, 2003; 63(6): 1398 - 1406.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
G. K. Wang and S.-Y. Wang
Veratridine block of rat skeletal muscle Nav1.4 sodium channels in the inner vestibule
J. Physiol., May 1, 2003; 548(3): 667 - 675.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
H. Liu, J. Atkins, and R. S. Kass
Common Molecular Determinants of Flecainide and Lidocaine Block of Heart Na+ Channels: Evidence from Experiments with Neutral and Quaternary Flecainide Analogues
J. Gen. Physiol., February 24, 2003; 121(3): 199 - 214.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/38/35393    most recent
M206126200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yarov-Yarovoy, V.
Right arrow Articles by Catterall, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yarov-Yarovoy, V.
Right arrow Articles by Catterall, W. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement